LONG-TERM COST-EFFECTIVENESS OF IGLARLIXI VERSUS IDEGLIRA IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES TREATED WITH BASAL INSULIN OR ORAL ANTIDIABETIC DRUG IN CHINA

被引：0
|
作者：
Mo, X. [1 ]
Ai, Y. [2 ]
Tan, J. [3 ]
Wang, L. J. [3 ]
机构：
[1] IQVIA China, Real World Solut, Shanghai 31, Peoples R China
[2] IQVIA China, Real World Solut, Shanghai, Peoples R China
[3] Sanofi, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE107
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [31] Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand
    Permsuwan, Unchalee
    Chaiyakunapruk, Nathorn
    Dilokthornsakul, Piyameth
    Thavorn, Kednapa
    Saokaew, Surasak
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (03) : 281 - 292
  • [32] Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand
    Unchalee Permsuwan
    Nathorn Chaiyakunapruk
    Piyameth Dilokthornsakul
    Kednapa Thavorn
    Surasak Saokaew
    Applied Health Economics and Health Policy, 2016, 14 : 281 - 292
  • [33] Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
    Ran Wei
    Weihao Wang
    Xiusheng Huang
    Jingtao Qiao
    Jinghe Huang
    Chang Xing
    Qi Pan
    Lixin Guo
    Diabetology & Metabolic Syndrome, 15
  • [34] Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
    Wei, Ran
    Wang, Weihao
    Huang, Xiusheng
    Qiao, Jingtao
    Huang, Jinghe
    Xing, Chang
    Pan, Qi
    Guo, Lixin
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [35] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets
    Cannon, Anthony J.
    Bargiota, Alexandra
    Billings, Liana
    Hunt, Barnaby
    Leiter, Lawrence A.
    Malkin, Samuel
    Mocarski, Michelle
    Ranthe, Mattis Flyvholm
    Schiffman, Alisa
    Doshi, Ankur
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 143 - 153
  • [36] Long-term cost-effectiveness of insulin aspart versus soluble human insulin in patients with type 1 diabetes in the United Kingdom
    Minshall, ME
    Twena, NS
    Nicklasson, L
    Roze, S
    VALUE IN HEALTH, 2005, 8 (03) : 358 - 359
  • [37] COST-EFFECTIVENESS OF LIXISENATIDE COMBINED WITH BASAL INSULIN VERSUS INSULIN REGIMENS FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN IN CHINA
    Men, P.
    Qu, S.
    Luo, W.
    Li, C.
    Zhai, S.
    VALUE IN HEALTH, 2019, 22 : S150 - S150
  • [38] Cost-effectiveness of lixisenatide combined with basal insulin versus insulin regimens for the treatment of patients in China with type 2 diabetes mellitus inadequately controlled by basal insulin
    Men, Peng
    Qu, Shuli
    Luo, Wenting
    Li, Chaoyun
    Zhai, Suodi
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
  • [39] Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China
    James L. Palmer
    Amélie Beaudet
    Jeremy White
    Juliette Plun-Favreau
    Jayne Smith-Palmer
    Advances in Therapy, 2010, 27 : 814 - 827
  • [40] Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China
    Palmer, James L.
    Beaudet, Amelie
    White, Jeremy
    Plun-Favreau, Juliette
    Smith-Palmer, Jayne
    ADVANCES IN THERAPY, 2010, 27 (11) : 814 - 827
12345